Gambro beats Fresenius in Australia patent case:
This article was originally published in Clinica
An Australian federal court has ruled that Fresenius's dialysis concentrate and monitoring systems infringe a patent owned by Gambro subsidiary Gambro Lundia. The patent covers the BiCart dry concentrate system. Fresenius has been banned from distributing its biBag product in Australia, and damages due to Gambro will be assessed. However, Fresenius may appeal and the enforcement of the injunction will be stayed until the appeal has been decided. Dry concentrate systems are designed to reduce the risk of contamination and bacterial growth associated with liquid bicarbonate concentrates, and account for about 20% of the worldwide concentrate market.